Dr.Yanagiya from ARCALIS will present a poster and serve as session chair at the TIDES ASIA 2024. Please visit us.

【Overview of the TIDES ASIA】
TIDES Asia: Oligonucleotide & Peptide Therapeutics (informaconnect.com)
【Date and location】 March 19th to 21st, 2024 Westin Miyako Kyoto Kyoto, Japan
【Poster Topic】RNA Therapeutics and Vaccines
【Onsite Poster BoardAssignment Number】 23
【Poster Reference Number】TIDESASIA24_18_Yanagiya
【Poster Display】Tuesday, March 20th: 11:00AM-2:00PM JST      

【Abstruct】
ARCALIS was established as a CDMO for mRNA vaccine and therapeutics, which have emerged as practical clinical applications recent years. ARCALIS has provided customers with seamless services from mRNA therapeutics development to large-scale manufacturing. Our drug substance plant was launched to manufacture mRNA medicine in Minami-Soma, Fukushima in 2023, in which a drug product plant to manufacture mRNA-LNP and a MD plant to manufacture template DNA will be constructed in 2026 and 2027, respectively.
Kostaive was approved in Japan as a self-amplifying mRNA (saRNA) for COVID-19 vaccine for the first time in the world, which is manufactured in ARCALIS’s Minami-Soma plant.
ARCALIS provides seamless services for mRNA therapeutics from CMC development to manufacturing. ARCALIS also provides innovative mRNA design by our original codon optimization algorithms along with unique 5’ and 3’ UTRs for efficient protein expression according to the customers’ needs. In collaboration with ADDP, ARCALIS evaluates mRNA potencies by in vivo/vitro experiments.
◎　Akiko Yanagiya, Rena Akahori, Hiroaki Murakami, Azusa Tanaka, Yanwen Feng, Hayato Sato, Naoki Matsumoto, Daichi Matsuura, Jun Nihira, Tetsuo Yoshida, Yuki Hasegawa, Kazuyuki Nakashima

【Chairperson】
Track #1
Wednesday 21st: 10:55AM-12:30 PM JST
Track #1
Wednesday 21st: 13:30PM-15:05 PM JST
Track #1
Wednesday 21st: 15:35PM-17:05 PM JST